Galapagos NV
GLPG | BR
Overview
Corporate Details
- ISIN(s):
- BE0003818359
- LEI:
- 549300QKJ78IY0IOV655
- Country:
- Belgium
- Address:
- Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3, 2800 Mechelen
- Website:
- https://www.glpg.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
We are a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-24 06:29 |
Board/Management Change
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Acc…
|
Dutch | 274.4 KB | |
| 2025-07-24 06:29 |
Board/Management Change
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Acc…
|
English | 262.1 KB | |
| 2025-07-24 06:28 |
Board/Management Change
Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Gr…
|
English | 248.2 KB | |
| 2025-07-24 06:28 |
Board/Management Change
Galapagos verwelkomt ervaren farmaceutische leidinggevenden Dawn Svoronos en Ja…
|
Dutch | 269.0 KB | |
| 2025-07-24 06:27 |
Earnings Release
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter …
|
English | 354.4 KB | |
| 2025-07-24 06:27 |
Earnings Release
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter …
|
Dutch | 372.1 KB | |
| 2025-07-23 22:01 |
Earnings Release
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter …
|
English | 373.8 KB | |
| 2025-07-23 22:01 |
Earnings Release
Galapagos rapporteert halfjaarcijfers 2025 en geeft een update over de activite…
|
Dutch | 462.5 KB | |
| 2025-07-23 22:01 |
Interim Report
Galapagos Half-Year report 2025.pdf
|
English | 3.4 MB | |
| 2025-07-23 22:01 |
Interim Report
Galapagos Halfjaarverslag 2025.pdf
|
Dutch | 3.4 MB | |
| 2025-06-23 08:37 |
Board/Management Change
Galapagos benoemt Aaron Cox als Chief Financial Officer
|
Dutch | 280.5 KB | |
| 2025-06-23 08:37 |
Board/Management Change
Galapagos benoemt Aaron Cox als Chief Financial Officer
|
English | 268.4 KB | |
| 2025-06-23 07:30 |
Board/Management Change
Galapagos Press Release_CFO_ENG.pdf
|
English | 268.4 KB | |
| 2025-06-23 07:30 |
Board/Management Change
Galapagos Press Release_CFO_NL.pdf
|
Dutch | 280.5 KB | |
| 2025-06-19 07:38 |
Earnings Release
Company announcement
|
Dutch | 347.4 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-22 | EcoR1 Capital Fund Qualified, L.P. | Close relation | Buy | 58,375 | 1,681,760.40 USD |
| 2025-05-22 | EcoR1 Capital Fund, L.P. | Close relation | Buy | 3,898 | 112,299.82 USD |
| 2025-05-20 | EcoR1 Capital Fund Qualified, L.P. | Close relation | Buy | 14,321 | 412,553.64 USD |
| 2025-05-20 | EcoR1 Capital Fund, L.P. | Close relation | Buy | 956 | 27,540.07 USD |
| 2025-05-19 | EcoR1 Capital Fund Qualified, L.P. | Close relation | Buy | 9,376 | 261,151.60 USD |
| 2025-05-19 | EcoR1 Capital Fund, L.P. | Close relation | Buy | 626 | 17,436.10 USD |
| 2025-05-16 | EcoR1 Capital Fund Qualified, L.P. | Close relation | Buy | 39,112 | 1,077,934.54 USD |
| 2025-05-16 | EcoR1 Capital Fund, L.P. | Close relation | Buy | 2,612 | 71,987.24 USD |
| 2025-05-15 | EcoR1 Capital Fund Qualified, L.P. | Close relation | Buy | 187,480 | 5,015,090.00 USD |
| 2025-05-15 | EcoR1 Capital Fund, L.P. | Close relation | Buy | 12,520 | 334,910.00 USD |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |